MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance

Figure 4

Exposure of T-leukemia/lymphoma cells to chemotherapeutic agents upregulated miR181a expression and resulted in AKT activation. (a) When Jurkat cells were treated with chemotherapeutic agents for 48 h, miR181a expression was significantly increased. CON, untreated; DOX, doxorubicin; CTX, cyclophosphamide; Ara-C, cytarabine. ; ; comparing with the CON cells. (b) In accordance with miR181a upregulation, increased AKT phosphorylation was observed by western blot, while the total protein level remained constant. (c) and (d) IC50 of doxorubicin was significantly increased in doxorubicin-resistant Jurkat (c) and H9 (d) cells, which were exposed to doxorubicin for 3 weeks. (e) and (f) MiR181a expression was significantly increased in doxorubicin-resistant Jurkat (e) and H9 (f) cells. CON, untreated; ; comparing with the CON cells. (g) and (h) P-AKT expression was significantly increased in doxorubicin-resistant Jurkat (g) and H9 (h) cells.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)